Todas las investigaciones
ReclutamientoConfirmatorio terapéutico (Fase III)Intervencionista

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

This research study is for people in the UK who have follicular lymphoma, which is a type of blood cancer that affects certain white blood cells. This study is testing a new drug called Ibrutinib. Researchers want to see if combining Ibrutinib with another standard drug, Rituximab, is more effective than just Rituximab alone. Participants will be randomly assigned to one of two groups: one group will receive Ibrutinib plus Rituximab, and the other will receive a dummy drug (placebo) plus Rituximab. The main goal is to find out if the Ibrutinib combination helps people live longer without their cancer getting worse, and to understand any side effects. This is a crucial step in finding better treatments for follicular lymphoma.

De un vistazo

Estado
Reclutamiento
Fase
Confirmatorio terapéutico (Fase III)
Patrocinador
AbbVie Deutschland GmbH & Co. KG
Objetivo de inscripción
231
Inicio
19 Feb 2024

¿De qué trata este estudio?

This research study, called a clinical trial, is looking for a better way to treat follicular lymphoma. This is a type of cancer that starts in certain white blood cells called lymphocytes. When you're first diagnosed with follicular lymphoma and haven't had treatment before, doctors look for the best treatment to help you.

In this study, they are investigating a new drug called Ibrutinib. This drug works by targeting a specific protein in the cancer cells. The researchers want to see if adding Ibrutinib to a standard treatment, Rituximab, is more effective than the standard treatment alone. Rituximab is a common treatment for follicular lymphoma that helps your immune system fight the cancer cells.

The main aim is to find out if people who receive Ibrutinib along with Rituximab live longer without their cancer growing or getting worse. This is an important measure because it tells us how well the treatment is controlling the cancer. The study will also carefully check for any side effects and how people feel overall. By understanding these results, doctors can make better decisions about future treatments for follicular lymphoma.

Puntos clave

  • This study is for people with newly diagnosed follicular lymphoma.
  • It's comparing a new drug (Ibrutinib) with a standard treatment (Rituximab).
  • The main goal is to see if Ibrutinib helps people live longer without their cancer worsening.
  • Participants will be randomly assigned to one of two treatment groups.
  • All study visits and treatments will be provided by the research team.
  • You can stop participating at any time you wish.

¿Quién puede ser elegible?

This study is looking for adults who are at least 18 years old. Both men and women can take part.

To be eligible, you must have been recently diagnosed with follicular lymphoma and have not yet received any treatment for it. This is important because the study wants to see how the new treatment works in people who are just starting their cancer journey.

There will be other detailed health checks to make sure the study is safe and suitable for you. These will be discussed with you by the study doctor or nurse to see if you meet all the requirements.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Have you been diagnosed with follicular lymphoma?
  3. Have you NOT received any treatment for your follicular lymphoma yet?
  4. Are you able to take capsules by mouth?
  5. Are you willing to attend regular hospital or clinic visits?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you will be randomly placed into one of two groups. Neither you nor your doctor will know which group you are in. One group will receive the new drug Ibrutinib along with Rituximab, and the other group will receive a dummy pill (placebo) along with Rituximab. The Ibrutinib or placebo is a capsule you take by mouth.

You will have regular visits to the hospital or clinic for treatments, check-ups, and to monitor how you are doing. These visits will involve blood tests, physical examinations, and possibly scans to see how your cancer is responding and to check for any side effects. The study also looks at how long the treatment keeps the cancer under control.

The exact length of your participation will depend on how you respond to the treatment and the study's design. The study team will explain the full schedule of visits and assessments to you before you agree to take part.

Riesgos y beneficios potenciales

Taking part in a clinical trial might offer potential benefits, such as access to a new treatment (Ibrutinib) before it's widely available. The treatment might be more effective at controlling your follicular lymphoma than standard care. However, there are also potential risks, including side effects from the study drugs. These side effects can vary from mild to severe, and the study team will monitor you closely for them. You will be given detailed information about known side effects before you decide to join. It is very important to remember that participating in any clinical trial is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (11)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Italia
  • —
    No verificado
    Greece
  • —
    No verificado
    Austria
  • —
    No verificado
    Países Bajos
  • —
    No verificado
    Hungría
  • —
    No verificado
    Chequia
  • —
    No verificado
    Polonia
  • —
    No verificado
    Bélgica
  • —
    No verificado
    España
  • —
    No verificado
    Portugal
  • —
    No verificado
    Francia

Preguntas comunes

What is Ibrutinib?

Ibrutinib is a new drug being tested that aims to block a specific protein involved in the growth of follicular lymphoma cells.

¿Qué es un 'placebo'?

A placebo is a dummy pill that looks exactly like the study drug but contains no active medicine. It helps researchers compare the effects of the active drug.

Will I know which treatment I'm getting?

No, this is a 'double-blind' study, meaning neither you nor your doctors will know if you're getting Ibrutinib or the placebo. This helps ensure fair and unbiased results.

What does 'progression-free survival' mean?

It's a way for doctors to measure how long people live without their cancer getting worse or growing. It helps measure how effective a treatment is at controlling the cancer.

¿Puedo abandonar el estudio si cambio de opinión?

Yes, absolutely. Your participation is completely voluntary, and you can withdraw from the study at any time without having to give a reason.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Multicenter, Randomized, Double-blind, Placebo-controlled …" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.